BR112017010595A2 - análogos de ureia com ligações por pontes substituídas como moduladores de sirtuína - Google Patents

análogos de ureia com ligações por pontes substituídas como moduladores de sirtuína

Info

Publication number
BR112017010595A2
BR112017010595A2 BR112017010595-0A BR112017010595A BR112017010595A2 BR 112017010595 A2 BR112017010595 A2 BR 112017010595A2 BR 112017010595 A BR112017010595 A BR 112017010595A BR 112017010595 A2 BR112017010595 A2 BR 112017010595A2
Authority
BR
Brazil
Prior art keywords
diseases
disorders
sirtuin modulators
substituted bridged
compounds
Prior art date
Application number
BR112017010595-0A
Other languages
English (en)
Inventor
Lamond Ellis James
Anderson Evans Karen
Michael Fox Ryan
Henry Miller William
Andrew Seefeld Mark
Original Assignee
GlaxoSmithKline Intellectual Property
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property filed Critical GlaxoSmithKline Intellectual Property
Publication of BR112017010595A2 publication Critical patent/BR112017010595A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4995—Pyrazines or piperazines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

resumo ?análogos de ureia com ligações por pontes substituídas como moduladores de sirtuína? a presente invenção refere-se a novos compostos análogos de ureia com ligações por pontes substituídas de fórmula (i) ou sais farmaceuticamente aceitáveis dos mesmos, composições farmacêuticas correspondentes, processos para a produção e uso de tais compostos, isoladamente ou em combinação com outros agentes terapêuticos, como moduladores de sirtuína, úteis para aumentar o tempo de vida de uma célula e para tratar e/ou prevenir uma grande variedade de doenças e distúrbios, que incluem, mas não se limitam a, por exemplo, doenças ou distúrbios relacionados ao envelhecimento ou estresse, diabetes, obesidade, doenças neurodegenerativas, doenças cardiovasculares, distúrbio da coagulação sanguínea, inflamação, câncer e/ou flushing, bem como doenças ou distúrbios que se beneficiariam do aumento da atividade mitocondrial.
BR112017010595-0A 2014-11-19 2015-11-19 análogos de ureia com ligações por pontes substituídas como moduladores de sirtuína BR112017010595A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462081916P 2014-11-19 2014-11-19
US62/081,916 2014-11-19
PCT/IB2015/058977 WO2016079709A1 (en) 2014-11-19 2015-11-19 Substituted bridged urea analogs as sirtuin modulators

Publications (1)

Publication Number Publication Date
BR112017010595A2 true BR112017010595A2 (pt) 2018-01-02

Family

ID=54705247

Family Applications (4)

Application Number Title Priority Date Filing Date
BR112017010599A BR112017010599A2 (pt) 2014-11-19 2015-11-19 análogos de ureia ligada substituída como moduladores sirtuin
BR112017010601A BR112017010601A2 (pt) 2014-11-19 2015-11-19 análogos de ureia substituídos em ponte como moduladores de sirtuínas
BR112017010595-0A BR112017010595A2 (pt) 2014-11-19 2015-11-19 análogos de ureia com ligações por pontes substituídas como moduladores de sirtuína
BR112017010602A BR112017010602A2 (pt) 2014-11-19 2015-11-19 análogos de ureia ligados em ponte substituídos como moduladores de sirtuína

Family Applications Before (2)

Application Number Title Priority Date Filing Date
BR112017010599A BR112017010599A2 (pt) 2014-11-19 2015-11-19 análogos de ureia ligada substituída como moduladores sirtuin
BR112017010601A BR112017010601A2 (pt) 2014-11-19 2015-11-19 análogos de ureia substituídos em ponte como moduladores de sirtuínas

Family Applications After (1)

Application Number Title Priority Date Filing Date
BR112017010602A BR112017010602A2 (pt) 2014-11-19 2015-11-19 análogos de ureia ligados em ponte substituídos como moduladores de sirtuína

Country Status (21)

Country Link
US (4) US10072011B2 (pt)
EP (4) EP3221322A1 (pt)
JP (4) JP2017534663A (pt)
KR (4) KR20170083134A (pt)
CN (4) CN107207520A (pt)
AU (4) AU2015348941A1 (pt)
BR (4) BR112017010599A2 (pt)
CA (4) CA2968027A1 (pt)
CL (1) CL2017001275A1 (pt)
CO (1) CO2017004994A2 (pt)
CR (1) CR20170209A (pt)
DO (1) DOP2017000123A (pt)
EA (1) EA201791074A1 (pt)
ES (1) ES2823748T3 (pt)
IL (1) IL252252A0 (pt)
MX (1) MX2017006658A (pt)
PE (1) PE20171257A1 (pt)
PH (1) PH12017500913A1 (pt)
RU (3) RU2017120858A (pt)
SG (1) SG11201703824QA (pt)
WO (4) WO2016079709A1 (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016086088A2 (en) 2014-11-25 2016-06-02 Northwestern University Wound healing through sirt1 overexpression
CN108329388A (zh) * 2018-01-18 2018-07-27 天津市湖滨盘古基因科学发展有限公司 一种人的沉默配型信息调节蛋白突变蛋白及其应用
CN108395436B (zh) * 2018-05-14 2021-01-12 鹤壁市人民医院 一种咪唑并吡嗪医药中间体的制备方法
CN108707150B (zh) * 2018-05-14 2021-04-16 江苏惠利生物科技有限公司 一种咪唑并吡嗪医药中间体的制备方法
CN110478339A (zh) * 2019-08-12 2019-11-22 昆明理工大学 紫铆因在制备靶向恢复突变p53构象药物中的应用
KR20220056223A (ko) * 2019-09-02 2022-05-04 메르크 파텐트 게엠베하 유기 전계발광 디바이스용 재료
CN114890955A (zh) * 2022-06-23 2022-08-12 江西瑞威尔生物科技有限公司 一种n取代吗啉类有机化合物的制备工艺

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4727064A (en) 1984-04-25 1988-02-23 The United States Of America As Represented By The Department Of Health And Human Services Pharmaceutical preparations containing cyclodextrin derivatives
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
WO2006094210A2 (en) * 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. Tetrahydroquinoxalinone sirtuin modulators
UA108596C2 (xx) 2007-11-09 2015-05-25 Інгібітори пептиддеформілази
US9556201B2 (en) * 2009-10-29 2017-01-31 Glaxosmithkline Llc Bicyclic pyridines and analogs as sirtuin modulators
JP2015504868A (ja) * 2011-12-12 2015-02-16 エスエムビー・イノベーション・アンパルトセルスカブＳＭＢ Ｉｎｎｏｖａｔｉｏｎ ＡｐＳ サーチュイン結合および調節に有用な新規複素環化合物
WO2014186313A1 (en) * 2013-05-13 2014-11-20 Glaxosmithkline Llc Substituted bridged urea analogs as sirtuin modulators

Also Published As

Publication number Publication date
JP6806679B2 (ja) 2021-01-06
US10072011B2 (en) 2018-09-11
KR20170087907A (ko) 2017-07-31
IL252252A0 (en) 2017-07-31
CR20170209A (es) 2017-07-17
BR112017010599A2 (pt) 2017-12-26
KR20170083135A (ko) 2017-07-17
JP2017534663A (ja) 2017-11-24
PE20171257A1 (es) 2017-08-28
EP3221317B1 (en) 2020-07-22
CA2968029A1 (en) 2016-05-26
CN107207509B (zh) 2020-04-21
EP3221316A1 (en) 2017-09-27
CA2968030A1 (en) 2016-05-26
AU2015348943A1 (en) 2017-06-01
AU2015348944A1 (en) 2017-06-01
BR112017010602A2 (pt) 2017-12-26
ES2823748T3 (es) 2021-05-10
JP2017534664A (ja) 2017-11-24
KR20170083133A (ko) 2017-07-17
RU2017120857A (ru) 2018-12-19
RU2017120858A (ru) 2018-12-19
WO2016079712A1 (en) 2016-05-26
US20180319810A1 (en) 2018-11-08
DOP2017000123A (es) 2017-08-15
CA2968032A1 (en) 2016-05-26
MX2017006658A (es) 2018-01-15
SG11201703824QA (en) 2017-06-29
CO2017004994A2 (es) 2017-09-20
WO2016079710A1 (en) 2016-05-26
WO2016079711A1 (en) 2016-05-26
BR112017010601A2 (pt) 2017-12-26
PH12017500913A1 (en) 2017-12-04
EP3221322A1 (en) 2017-09-27
EP3220918A1 (en) 2017-09-27
US20170355705A1 (en) 2017-12-14
CN107207509A (zh) 2017-09-26
AU2015348941A1 (en) 2017-06-01
RU2017120855A (ru) 2018-12-19
CN107207521A (zh) 2017-09-26
EP3221317A1 (en) 2017-09-27
EA201791074A1 (ru) 2017-10-31
JP2017534665A (ja) 2017-11-24
CN107108627A (zh) 2017-08-29
US20190048016A1 (en) 2019-02-14
CA2968027A1 (en) 2016-05-26
JP2017534662A (ja) 2017-11-24
KR20170083134A (ko) 2017-07-17
WO2016079709A1 (en) 2016-05-26
CN107207520A (zh) 2017-09-26
AU2015348942B2 (en) 2018-07-05
US20170362234A1 (en) 2017-12-21
AU2015348942A1 (en) 2017-06-01
CL2017001275A1 (es) 2017-12-15

Similar Documents

Publication Publication Date Title
BR112017010595A2 (pt) análogos de ureia com ligações por pontes substituídas como moduladores de sirtuína
CO2017011851A2 (es) Compuestos novedosos
UY35391A (es) Acido 2-aza-biciclo[2.2.1]heptano-3-carboxilico (bencil-cianometil)-amidas sustituidas inhibidores de catepsina c
BR112017010592A2 (pt) análogos de ureia ligados em ponte substituídos como moduladores de sirtuína
BR112017009657A2 (pt) análogos de ácidos biliares como agonistas de fxr/tgr5 e métodos de uso dos mesmos
CY1121710T1 (el) Παρεμβασεις με βαση την αγγειοποιητινη για τη θεραπεια της εγκεφαλικης ελονοσιας
CR20130410A (es) Compuestos y composiciones como inhibidores de la trk
ECSP17046848A (es) Nuevos compuestos y composiciones farmacéuticas de los mismos para el tratamiento de desórdenes inflamatorios y osteoartritis
BR112015027114A2 (pt) novos compostos para os inibidores seletivos de histona desacetilase, e composição farmacêutica compreendendo os mesmos
PE20150631A1 (es) Formas cristalinas de un modulador del receptor androgenico
BR112012010010A2 (pt) piridinas bicíclicas e análogos como moduladores da sirtuína
BR112018005861A2 (pt) derivados de ácido oleanólico modificado com c4 para a inibição de il-17 e outros usos
CY1119047T1 (el) Υποκατεστημενα βενζαμιδια με δραστικοτητα εναντι υποδοχεων ερ4
CL2015002434A1 (es) Moduladores benzoimidazol-2-il pirimidinas del receptor h4 de histamina.
BR112014003704A2 (pt) moduladores ror gama
DOP2015000005A (es) Derivados de estra 1,3,5(10), 16 tetraeno 3 sustituidos, métodos para su preparación, preparaciones farmacéuticas que los contienen, así como su uso para la preparación de medicamentos
BR112017003745A2 (pt) inibidores de semialdeído descarboxilase de ácido alfa-amino-beta-carboximucônico
ECSP14002542A (es) Nuevos 2h–indazoles como antagonistas del receptor ep2
UY35668A (es) Derivados de azabencimidazol como agonistas de ampk y composiciones farmacéuticas que los contienen
BR112017007025A2 (pt) sulfatos de colesterol oxigenados para terapia de distúrbios causados por pelo menos um de atividade de leptina atenuada e um distúrbio de armazenamento de lipídio
UY37729A (es) NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7
UY33529A (es) Composiciones farmacéuticas para el tratamiento de enfermedades respiratorias e inflamatorias?
UY35785A (es) Derivados de piperazina sustituidos como moduladores del transportador de la glicina-1 (glyt1)
UY31646A1 (es) Uso de fenilimidazolidinas sustituidas para producir medicamentos para el tratamiento del síndrome metabólico
BR112017003227A2 (pt) composto, composição farmacêutica e uso de um composto

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]